LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Reactivation of COVID-19 pneumonia: A report of two cases.

    Ravioli, Svenja / Ochsner, Hannah / Lindner, Gregor

    The Journal of infection

    2020  Volume 81, Issue 2, Page(s) e72–e73

    MeSH term(s) Aged ; Aged, 80 and over ; Anti-Bacterial Agents/therapeutic use ; Azithromycin/therapeutic use ; Betacoronavirus/pathogenicity ; Betacoronavirus/physiology ; COVID-19 ; Coronavirus Infections/diagnostic imaging ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Fatal Outcome ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Pandemics ; Pneumonia, Viral/diagnostic imaging ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Radiography ; SARS-CoV-2 ; Tomography, X-Ray Computed ; Virus Activation ; Virus Latency
    Chemical Substances Anti-Bacterial Agents ; Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5)
    Keywords covid19
    Language English
    Publishing date 2020-05-07
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2020.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1501: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 48: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Reactivation of COVID-19 pneumonia

    Ravioli, Svenja / Ochsner, Hannah / Lindner, Gregor

    Journal of Infection

    A report of two cases

    2020  Volume 81, Issue 2, Page(s) e72–e73

    Keywords Microbiology (medical) ; Infectious Diseases ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2020.05.008
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1501: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 48: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Reactivation of COVID-19 in a neurosurgical patient with early neuropsychiatric presentation. Does seroconversion mean immunity?

    Bonomo, Giulio / Caldiroli, Dario / Bonomo, Roberta / Pugliese, Raffaelino / DiMeco, Francesco / Zoia, Cesare

    Surgical neurology international

    2021  Volume 12, Page(s) 166

    Abstract: ... of COVID-19 reactivation associated with a neurosurgical operation with early neuropsychiatric involvement ... Conclusion: Our report highlights the importance of comprehensive screening assessments in sensitive cases ... Background: In the aftermath of COVID-19 outbreak, there is a strong need to find strategies ...

    Abstract Background: In the aftermath of COVID-19 outbreak, there is a strong need to find strategies to monitor SARSCoV-2 transmission. While the application of screening techniques plays a major role to this end, there is evidence challenging the real significance of seroconversion. We reported a case of COVID-19 reactivation associated with a neurosurgical operation with early neuropsychiatric involvement presumably promoted by olfactory and gustatory impairment in the first infection.
    Case descriptio: A 57-year-old man was referred for a 2-month history of progressive development of imbalance, dizziness, and vomiting. Magnetic resonance imaging showed two bilateral hemispheric cerebellar lesions. In line with our triage protocol, the patient underwent a nasopharyngeal swab for RNA of SARS-CoV-2 detection, which resulted positive. Of note, the patient had reported in the previous month hyposmia and hypogeusia. After a period of 14 days, three new swabs were performed with negative results, leading the way to surgery. In the early post-operative period, the patient manifested acute onset of psychotic symptoms with hyperactive delirium, followed by fever and acute respiratory failure. A chest computed tomography revealed a specific pattern of ground-glass opacities in the lower lobes bilaterally, suggesting a viral pneumonia. Serological tests demonstrated the seroconversion and a new nasopharyngeal swab confirmed SARS-CoV-2 infection.
    Conclusion: Our report highlights the importance of comprehensive screening assessments in sensitive cases highly susceptible to COVID-19 recurrence.
    Language English
    Publishing date 2021-04-19
    Publishing country United States
    Document type Case Reports
    ISSN 2229-5097
    ISSN 2229-5097
    DOI 10.25259/SNI_831_2020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.

    Lancman, Guido / Mascarenhas, John / Bar-Natan, Michal

    Journal of hematology & oncology

    2020  Volume 13, Issue 1, Page(s) 131

    Abstract: ... She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic ... cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high ... and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June ...

    Abstract SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. She was discharged home in stable condition several days later. Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.
    MeSH term(s) Acute Disease ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Anticoagulants/therapeutic use ; Betacoronavirus/genetics ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Cytarabine/adverse effects ; Cytarabine/therapeutic use ; Female ; Humans ; Immunization, Passive ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Middle Aged ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Polymerase Chain Reaction ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Recurrence ; Rituximab/adverse effects ; Rituximab/therapeutic use ; SARS-CoV-2 ; Steroids/therapeutic use ; Treatment Outcome ; COVID-19 Drug Treatment ; COVID-19 Serotherapy
    Chemical Substances Antibodies, Viral ; Anticoagulants ; Immunosuppressive Agents ; Steroids ; Cytarabine (04079A1RDZ) ; Rituximab (4F4X42SYQ6)
    Keywords covid19
    Language English
    Publishing date 2020-10-02
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 2429631-4
    ISSN 1756-8722 ; 1756-8722
    ISSN (online) 1756-8722
    ISSN 1756-8722
    DOI 10.1186/s13045-020-00968-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.

    Dalla Via, Vera / von Rotz, Matthias / Bättig, Veronika / Leuzinger, Karoline / Hirsch, Hans H / Passweg, Jakob / Stüssi, Georg / Medinger, Michael

    SN comprehensive clinical medicine

    2021  Volume 3, Issue 10, Page(s) 2011–2015

    Abstract: ... hospitalized a month prior because of a COVID-19 bilateral pneumonia. On discharge, he showed two negative SARS ... for acute myeloid leukemia (AML). He received the first dose of a COVID-19 vaccine 6 weeks prior allo-HSCT and was ... about reactivation in immunocompromised patients. Here, we report the case of a 61-year-old male undergoing ...

    Abstract Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of a 61-year-old male undergoing a conditioning regimen with fludarabine, cyclophosphamide, and 2-Gy total body irradiation in preparation of a haplo-identical allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML). He received the first dose of a COVID-19 vaccine 6 weeks prior allo-HSCT and was hospitalized a month prior because of a COVID-19 bilateral pneumonia. On discharge, he showed two negative SARS-CoV-2 nasopharyngeal PCR swabs as well as a high SARS-CoV-2 antibody titer. On admission for allo-HSCT, he tested negative for SARS-CoV-2 again. Conditioning with fludarabine, cyclophosphamide, and 2-Gy total body irradiation was started and the patient developed lymphopenia. During his hospital stay, he tested positive for SARS-CoV-2 in a PCR test twice but remained asymptomatic. The conditioning regimen was continued as planned. Later during his stay, the patient showed undetectable SARS-CoV-2 load four times. This case documents possible reactivation of SARS-CoV-2 and raises questions about reactivation risks among recipients of stem cell transplants and other immunocompromised patients.
    Language English
    Publishing date 2021-07-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2947211-8
    ISSN 2523-8973 ; 2523-8973
    ISSN (online) 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-021-01020-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

    Guido Lancman / John Mascarenhas / Michal Bar-Natan

    Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-

    2020  Volume 3

    Abstract: ... She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic ... cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high ... and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June ...

    Abstract Abstract SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. She was discharged home in stable condition several days later. Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.
    Keywords COVID-19 ; SARS-CoV-2 ; Reactivation ; Rituximab ; Cytarabine ; Diseases of the blood and blood-forming organs ; RC633-647.5 ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; covid19
    Subject code 610
    Language English
    Publishing date 2020-10-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

    Lancman, G. / Mascarenhas, J. / Bar-Natan, M.

    J Hematol Oncol

    Abstract: ... a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ... cytarabine, and dasatinib She was initially hospitalized with COVID-19 in April and developed a high antibody ... dasatinib She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June She developed ...

    Abstract SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen She was discharged home in stable condition several days later Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #810384
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top